VIP is reliable and effective for treating LN, and its therapeutic mechanisms should be effective for modulating Th17/Treg immune homeostasis by downregulating serum levels of autoantibodies and renal levels of IL-17 and IL-6 and upregulating renal levels of Foxp3 and IL-10, thus ameliorating renal function defects, proteinuria and renal damage. Here, IL10 is linked to lobular neoplasia.